CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Lars Boesgaard

Profile

Lars Boesgaard

Chief Financial Officer (Principal Financial and Accounting Officer), PDS Biotechnology Corporation

Former. First published here October 28, 2026; built from records as of October 28, 2026.

PDS Biotechnology Corporation reported the departure of Lars Boesgaard from the chief financial officer seat, effective September 12, 2026.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
PDS Biotechnology Corporation (PDSB)
Pharmaceutical Preparations
Chief Financial Officer (Principal Financial and Accounting Officer)Former2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. September 12, 2026effective

    PDS Biotechnology Corporation reported the departure of Lars Boesgaard from the chief financial officer seat, effective September 12, 2026.

    On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue […]

    [2] Filing by PDS Biotechnology Corporation, filed with the SEC on August 19, 2026. Read the filing. The record at CFO Tribune.

  2. March 30, 202610-K filed

    Lars Boesgaard signed the annual report of PDS Biotechnology Corp on Form 10-K as Chief Financial Officer (Principal Financial and Accounting Officer), filed March 30, 2026.

    /s/ Lars Boesgaard Chief Financial Officer March 30, 2026 Lars Boesgaard (Principal Financial and Accounting Officer)

    [1] Annual report on Form 10-K by PDS Biotechnology Corp, filed with the SEC on March 30, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, PDS Biotechnology Corp. U.S. Securities and Exchange Commission, EDGAR, filed March 30, 2026. sec.gov; record.
  2. Current report filed with the SEC, PDS Biotechnology Corporation. U.S. Securities and Exchange Commission, EDGAR, filed August 19, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Lars Boesgaard wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.